GSK Settles for $3 Billion

December 2011
Pharmaceutical Representative;Dec2011, Vol. 41 Issue 12, p8
The article reports on the tentative agreement between pharmaceutical company GlaxoSmithKline (GSK) between the U.S. government to finalize an ongoing investigation on sales and marketing practices.


Related Articles

  • Glaxo reviews digital for consumer brands. Sweney, Mark // Campaign;2/14/2003, Issue 7, p3 

    Reports that the pharmaceutical company GlaxoSmithKline PLC is reviewing its digital agency suppliers working across brands. Reason behind the review.

  • GSK Resists the Urge to Merge. Houlton, Sarah // Pharmaceutical Executive;Sep2002, Vol. 22 Issue 9, p22 

    Reports on the statement made by GlaxoSmithKline that it is not interested in undertaking another big merger to increase its earnings prospects. Company's positive financial results in the second-quarter of 2002; Patent expirations and other challenges facing GlaxoSmithKline.

  • A healthy future for branded medicines? Singh, Sonoo // Marketing Week;7/13/2000, Vol. 23 Issue 24, p20 

    Reports on speculations on the offloading of consumer products by Glaxo Smithkline, the resulting company from the merger of Glaxo Wellcome and Smithkline Beecham. Issue of survival of nutritional consumer goods in Great Britain under the same roof as pharmaceutical products; Main problems with...

  • PROFESSIONAL MARKETING Update.  // Medical Marketing & Media;May2011, Vol. 46 Issue 5, p15 

    The article offers update related to the pharmaceutical industry including the increase in the request of online drug samples by physicians in 2010, the rate of lay-offs in the industry and the competition among sales representatives of GlaxoSmithKline in the emerging markets.

  • Illegal importation is bigger than just Canada. Eder, Rob // Drug Store News;5/19/2003, Vol. 25 Issue 7, p14 

    Focuses on GlaxoSmithKline's decision to cut off Canadian distributors that support illegal drug importation. Product safety; Patient-pharmacist interaction and compliance; Foot traffic.

  • GlaxoSmithKline.  // Fundweb;2/20/2014, p6 

    The article reports that according to investment research analyst Helal Miah, GlaxoSmithKline is the preferred stock in the pharmaceutical industry and the firm has a promising pipeline of new drugs.

  • THE WEEK IN HEALTHCARE.  // PRWeek (London);10/22/2010, p6 

    This section offers news briefs on the healthcare industry in Great Britain as of October 2010 including the release by GlaxoSmithKline of a medical communications brief for a diabetes drug, the appointment of Alexa Forbes as chief executive officer (CEO) at Packer Forbes, and the appointment of...

  • European Marketing Pact Signed.  // Drug Discovery & Development;Jan2002, Vol. 5 Issue 1, p19 

    Reports the acquisition of the rights to sell and distribute Natrecor in Europe by GlaxoSmithKline Plc. from Scios Inc.

  • Glaxo SmithKline Captures Leading Share of US Market. Mirasol, Feliza // Chemical Market Reporter;01/24/2000, Vol. 257 Issue 4, p5 

    Reports that Glaxo SmithKline, a combination of Glaxo Wellcome Inc. and SmithKline Beecham will be at the top of the pharmaceutical market. Competitive advantage of Glaxo SmithKline in the United States; Products that are expected to drive growth.


Read the Article


Sign out of this library

Other Topics